文献速递骨质疏松与代谢性骨病

英国临床实践研究数据链中女性骨质疏松治疗与颌骨坏死风险

Treatment for osteoporosis and risk of osteonecrosis of the jaw among female patients in the United Kingdom Clinical Practice Research Datalink.
PubMed 文献 · Osteoporos Int · 2024-10-14

在英国临床实践研究数据链Aurum中纳入467,654例40-89岁无癌症女性骨质疏松患者或高危者,当前使用抗骨吸收药物者颌骨坏死发生率为每10,000人年1.2例(95%CI 1.0-1.4)。与既往使用相比,治疗2-3年和10年后颌骨坏死比值比分别为3.0(95%CI 1.5-5.7)和8.1(95%CI 4.4-15),但绝对风险低(5年约0.05%,10年约0.18%),停药后6-9个月内升高风险降至接近零。

要点

  • 当前使用抗骨吸收药物(主要为阿仑膦酸钠)者颌骨坏死发生率为每10,000人年1.2例(95%CI 1.0-1.4)。
  • 与既往使用相比,治疗2-3年后颌骨坏死OR为3.0(95%CI 1.5-5.7),10年后OR为8.1(95%CI 4.4-15)。
  • 绝对风险低:5年约0.05%,10年约0.18%,停药后6-9个月内升高风险降至接近零。

核心结论

  • 使用抗骨吸收药物治疗2-3年后颌骨坏死风险增加,但绝对风险低,停药后不久即恢复至基线水平。

研究设计与样本

  • 在英国临床实践研究数据链Aurum中开展队列研究,纳入467,654例40-89岁无癌症的女性骨质疏松患者或高危者,随访至颌骨坏死诊断、90岁、记录结束或其他预设删失事件。
  • 采用算法和人工审核从CPRD Aurum及关联的医院 episode 统计数据库中选取颌骨坏死病例,并进行巢式病例对照分析。

主要发现

  • 共208例颌骨坏死病例;当前使用抗骨吸收药物(主要为阿仑膦酸钠)者发生率为每10,000人年1.2例(95%CI 1.0-1.4)。
  • 与既往使用抗骨吸收药物相比,治疗2-3年后颌骨坏死OR为3.0(95%CI 1.5-5.7),治疗10年后OR为8.1(95%CI 4.4-15)。
  • 绝对风险5年约0.05%,10年约0.18%;停药后6-9个月内升高风险降至接近零。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Osteonecrosis of the jaw (ONJ) is an adverse effect of antiresorptives. Among female patients treated for osteoporosis, ONJ risk was threefold higher after 2-3 years of treatment and eightfold after 10 years compared with past use. Absolute risks remained low (~ 0.05% after 5 years) and diminished after discontinuation. PURPOSE: Osteonecrosis of the jaw (ONJ) is a rare adverse effect of antiresorptive drug use; however, the magnitude of risk in osteoporosis patients has not been clearly described. METHODS: We conducted a cohort study among cancer-free female patients aged 40-89 with, or at risk for, osteoporosis in United Kingdom Clinical Practice Research Datalink (CPRD) Aurum. We followed patients from first osteoporosis treatment until first of osteonecrosis diagnosis, age 90, record end, or other prespecified censoring event, and accumulated person-time by osteoporosis treatment. ONJ cases were selected from CPRD Aurum and linked Hospital Episode Statistics data using an algorithm and manual review. We estimated incidence rates (IR) of ONJ by current treatment type and post discontinuation. We conducted a nested case-control analysis to further describe risk by cumulative dose and duration of antiresorptive therapies. RESULTS: Among 467,654 eligible patients, there were 208 ONJ cases. IR among patients currently treated with antiresorptives (primarily alendronate) was 1.2 (95% confidence interval [CI] 1.0-1.4) per 10,000 person-years. Compared with past use of antiresorptives, odds ratios of ONJ were 3.0 (95% CI 1.5-5.7) after 2-3 years of treatment and 8.1 (95% CI 4.4-15) after 10 years. However, absolute risks remained low (~ 0.05% after 5 years and ~ 0.18% after 10 years) and elevated risks diminished to near zero within 6 to 9 months of discontinuation. CONCLUSION: Risk of ONJ increased after 2-3 years of treatment with antiresorptives; however, the absolute risk was low and returned to baseline shortly after treatment discontinuation.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Persson R, Hagberg KW, Pranschke E, et al. Treatment for osteoporosis and risk of osteonecrosis of the jaw among female patients in the United Kingdom Clinical Practice Research Datalink. Osteoporos Int. 2024. PMID: 39400702. doi:10.1007/s00198-024-07262-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。